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Abstract : Monoclonal antibodies (mAbs) are highly complex proteins that display a wide range 
of microheterogeneity that requires multiple analytical methods for full structure assessment and 
quality control. As a consequence, the characterization of mAbs on different levels is particularly 
product - and time - consuming. This work presents the characterization of trastuzumab sequence 
using sheathless capillary electrophoresis (referred as CESI) – tandem mass spectrometry (CESI-
MS/MS). Using this bottom-up proteomic-like approach, CESI-MS/MS provided 100% 
sequence coverage for both heavy and light chain via peptide fragment fingerprinting (PFF) 
identification. The result was accomplished in a single shot, corresponding to the analysis of 100 
fmoles of digest. The same analysis also enabled precise characterization of the post-translational 
hot spots of trastuzumab, used as a representative widely marketed therapeutic mAb, including 
the structural confirmation of the five major N-glycoforms. 
Introduction 
Since 1986 and the approbation of muromonab-CD3 by the US Food and Drug Administration 
(FDA), monoclonal antibodies (mAbs) have taken a major market share in the pharmaceutical 
industry and their development is constantly increasing.1-2 MAbs are highly complex 
glycoproteins potentially displaying many naturally-occurring molecular micro-heterogeneities 
and those that are introduced through imperfect processing, physico-chemical and enzymatic 
changes that occur during their production and long-term conservation. As a consequence, there 
is a continuous need for improvement of analytical methods to enable fast and accurate 
characterization. Mass spectrometry (MS) plays a major role in the characterization of 
therapeutic mAbs because it provides specificity, sensitivity and may also provide structural 
information. Characterization using MS has helped product and process development3 and batch 
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consistency assessment.4,5 Furthermore, recent raising importance of biosimilar and biobetter 
mAbs represents a major stake for characterization methodologies. Biosimilar mAbs are 
produced from different clones and processes.6 The European Medicines Agency (EMA) and the 
FDA have published draft guidelines concerning the approval pathway of biosimilar mAbs. 
These documents discuss the physicochemical characterization steps required to assess 
biosimilarity. For example, EMA guidelines suggest that the biosimilar candidate should have 
the same amino acid sequence as the reference mAb and a comparable glycosylation profile.7 
The selection of a highly similar candidate to the innovator product is mandatory before 
performing pre-clinical and clinical biosimilarity studies. Obtaining suitable structural 
information rapidly, which allows quick elimination of candidates dissimilar to the reference 
protein, is therefore crucial. The methods used should cover a wide range of structural 
information, e.g. amino acid sequence, disulfide bonds, glycosylation, posttranslational 
modifications (PTM).8 Additional to MS, mAbs characterization requires a panel of orthogonal 
methods to cover a full range of structural information,9 including reverse phase liquid 
chromatography (RP-LC),10-12 ion exchange chromatography (IEC), size exclusion 
chromatography (SEC),13 capillary isoelectric focusing (cIEF)14 or micellar electrokinetic 
chromatography (MEKC).15, 16 
Peptide mapping of mAbs by MS is commonly performed using a bottom-up proteomic 
approach because it allows acquisition of information on the amino acid sequence and PTMs. In 
this approach, the protein undergoes enzymatic digestion, resulting in a peptide digest most often 
separated by liquid chromatography and detected by UV spectrophotometry and MS. 
A novel sheathless CE-ESI-MS platform, referred as CESI, allowing hyphenation of capillary 
electrophoresis (CE) to electrospray ionization mass spectrometry (ESI-MS) has been developed 
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by Beckman Coulter based on a design previously described by Moini.17 This CESI prototype 
(also known as sheathless capillary electrophoresis) uses a bare fused silica capillary whose 
outlet has been etched using hydrofluoric acid, which makes it porous to the electrical transport 
of small ions without permitting significant matter transfer through the pores. The porous tip 
provides electrical contact via a second capillary. Detailed description of this interface has been 
given by Haselberg et al.18 The sheathless interface has already been used to perform successful 
CE-ESI-MS experiments in proteomics,19-20 metabolomics,21 intact proteins22-23 demonstrating 
drastically increased sensitivity compared to sheath-liquid CE-MS due to operating flow rates of 
well below 100 nL/min. Whitmore and Gennaro recently used the CESI prototype to performed 
the peptide mass fingerprinting (PMF) of a mAb. They demonstrated the successful use of PMF 
to cover the amino sequence of a mAb, including the hydrophilic peptides that are eluted in the 
void volume in RP-LC-MS23. 
In this work, we used the CESI-MS system to develop a CE-MS/MS method that allowed the 
fast and precise characterization of a mAb digest. The mAb selected was trastuzumab which was 
approved by FDA and EMA, in 1998 and 2000 respectively. Trastuzumab has been intensively 
studied and can be considered as a highly representative therapeutic mAb.24 It is a humanized 
immunoglobulin gamma 1 (HzIgG-1) directed against the HER2/neu receptor which is 
overexpressed in about 20-30% of invasive breast cancer patients.25-26 Trastuzumab is composed 
of two heavy chains (HC) having 449 amino acids and two light chains (LC) having 214 amino 
acids.27 The HC has an N-glycosylation consensus site on its asparagine (Asn) in position 300, 
and the glycoprotein has a total molecular mass of about 148 kDa4. A tryptic digest of 
trastuzumab was prepared using a conventional in-solution digestion protocol.28 The digest was 
then studied at different levels. First a peptide mapping of the mAb was performed using a CESI-
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MS/MS analysis. The MS/MS spectra were automatically analyzed to identify the peptides using 
a search engine widely used in proteomic studies in order to hasten peptide identifications. PTMs 
were also characterized using CESI-MS/MS, particularly those known as degradation hot spots. 
These PTMs were identified by Mascot search algorithm and manually confirmed. At a final 
level, glycosylation were also investigated using CESI-MS/MS. Although glycosylation is a type 
of PTM, they are treated in this article separately from amino acid PTMs because they are not 
degradation hot spots. The glycans could be located on the amino acid sequence and the structure 
of the major glycoforms could be deduced from MS/MS data. Remarkably, the characterization 
of the mAb over these different described levels was realized using only one CESI-MS/MS 
analysis of the digest. 
 
Results 
Peptide mapping of trastuzumab using CESI-MS/MS. Peptide mapping is commonly used 
to determine protein amino acid sequence and to locate or quantify PTMs. This methodology is 
quite important in early development of therapeutic antibodies as well as during long term life 
cycle management of the biopharmaceutical products. As part of this work, one of the objective 
was to investigate the peptide mapping of trastuzumab by CESI-MS/MS. Tandem MS data 
interpretation and peptide identification was done automatically using Mascot to obtain fast and 
accurate data treatment.  
A sample of trastuzumab was digested with trypsin enzyme. Tryptic digestion was performed 
using an in-solution digestion protocol applied on a routine basis in the laboratory. It includes 
reduction and alkylation of disulfide bonds. Prior to digestion, an unfolding step was performed 
using guanidine as a chaotropic agent. Prior to MS analysis, peptides were separated using the 
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CESI prototype which allows direct coupling of CE with the nanospray source of the MS without 
using an additional liquid like in sheath-liquid CE-MS.29 
Figure 1 illustrates an example of the separation obtained for the tryptic digest of trastuzumab 
for 100 fmol of injected protein. The total duration of the separation was less than 50 min and the 
resulting electropherogram showed that all peptides were detected between 19 and 47 min. 
Separation was performed at a voltage of +20 kV to maintain a balance between peptide 
migration speed and separation efficiency. 
Digested peptides were identified from MS/MS data acquired using a Mascot search algorithm, 
although 100% sequence coverage of a mAb has already been reported using the prototype 
CESI-MS platform.23 In this work, peptide identification was automated and based on MS/MS 
data, meaning that identification was made on precursor ion mass measure and fragment 
identification. Results of Mascot search showed sequence coverage of 100% for both the HC and 
LC of the trastuzumab. The detailed sequence coverages for both chains are shown in Figure 2. 
Some peptides were selected and fragmented several times during the analysis leading to the 
same identification. Similarly, missed cleavages could be promptly detected for several peptides 
reinforcing the confidence of the identification by enabling peptide overlapping.  
Tryptic digestion produces a heterogeneous mixture of peptides, especially with regard to their 
number of amino acids. Results show the identification during the analysis of small peptides 
having 4-5 amino acids such as HT05 or LT09 (Figure 3) as well as a 63 amino acids peptide 
having a molecular mass of 6715.26 Da (HT21). During its elution, the ion corresponding to 
HT21 peptide was selected several time for fragmentation and resulted in the same identification, 
which reinforced the confidence of this important identification. 
 7 
It should be noted that such heavy peptides usually can attain higher charge state; therefore, the 
search algorithm must consider high charge state as well. In the CESI-MS/MS analysis of the 
mAb, peptides having charge state up to 6+ could be detected. Fragmentation of the peptides 
enables an important part of the amino acid sequence to be retraced reinforcing the high 
confidence in peptide identification.  
As seen in Figure 4, the MS/MS spectra quality, has allowed the amino acids sequence 
composing the variable domain of the mAb HC for 109 of 120 amino acids to be retraced. 
Similarly 98 of the 107 amino acids sequence composing the variable domain of the LC could be 
retraced using the MS/MS data. Thus, in addition to allowing the identification of the digested 
peptides of the mAb, the MS/MS spectra enabled characterization, without ambiguity, of most 
amino acids composing such a sensitive part of the mAb, i.e. the variable domain. 
To evaluate the robustness of the method, the CESI-MS/MS analysis of the mAb digest was 
repeated six times consecutively. Results of these analysis demonstrated 100% sequence 
coverage for each run and the same detected peptides in each analysis. 
Characterization of amino acids PTMs hot-spots. Mabs are  heterogeneous by nature 
because of structural modifications that the proteins may undergo during their lifetime. Those 
modifications may be Critical Quality Attributes (CQA) because they can modify the 
conformation of the protein and therefore influence the antibody activity. Posttranslational 
modifications and other physico-chemical modifications can be induced by intra or extra cellular 
processes, buffer, purification process, storage or stress conditions.31,32 Among those PTMs, 
several referred to as “hot spots” must be carefully monitored to determine the stability of the 
mAb during pharmaceutical development. Known degradation hot spots potentially modified on 
the HC are cyclization of N-terminal glutamic acid (Glu) into pyroglutamic acid and deamidation 
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of Asn55 and Asn387 but also oxidation of Met255 and Met431. The main hot spot on the LC is the 
deamidation Asp30. For the characterization of trastuzumab PTMs, the same CESI-MS/MS data 
presented in the previous section to obtain the mAb peptide mapping was used. In this case 
again, the PTMs were automatically identified by the Mascot search algorithm. Mass spectra 
were further manually studied to confirm the presence of the modifications. 
Results obtained showed glutamine cyclization of the N-terminal extremity of the HC. Also, 
the same peptide without the modification was identified, which suggests a partial modification 
of the protein. Use of the extracted ion electropherograms (XIE) for m/z ratio of 932.500 (2+) 
and 941.501 (2+) corresponding to the peptide HT01 with both N-terminal extremity forms 
allowed the determination of a migration time of 34.5 min for the intact form of HT01 and 45.6 
min for the modified HT01. This charge difference influences the electrophoretic mobility of the 
modified peptide, leading to its separation. 
In the same manner, several deamidation hot spots were also identified. Results presented in 
Figure 5 show the correct identification of the deamidation of Asn55 (HT04). In this case again 
the parent peptide could be identified without the modification as well, and the fragmentation 
allowed confirmation of the deamidation of this specific amino acid. Another deamidation hot 
spot present on the HC on Asn387 (HT41) was also characterized with the method. In this case 
again, the MS/MS spectra obtained for HT41 allowed the identification of the deamidation on 
this specific amino acid which is crucial because the digested peptide is composed of several 
Asn. Other micro-variants, such as methionine (Met) oxidation hot spots, were also identified by 
the algorithm using the CESI-MS/MS data. Results allowed the identification of the oxidations 
of Met255 (HT25) and Met431 (HT48) as a confirmation of the trend of a partial 
modification/degradation; both peptides could also be observed without any oxidation. The 
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peptide HT25 was detected at a time of 23.8 min for the intact form and 24.0 min for the 
oxidized HT25. A similar results could be observed for peptide HT48 as the intact peptide could 
be detected at 25.2 min and respectively at a time of 25.5 min for the oxidized HT25. Concerning 
the LC, the main deamidation hot spot located on Asn30 (LT03) was correctly identified by the 
algorithm. As for the other hot spots, the manual confirmation suggested a partial 
modification/degradation of the protein. 
These results unambiguously demonstrate the possibility of using CESI-MS to perform 
simultaneous MS/MS peptide mapping and amino acid PTM characterization. The separation of 
the digested peptide mixture allowed the MS to fragment a large number of ions, which enables 
the detection of PTMs. The mass spectra quality obtained using the CESI interface allowed the 
algorithm to successfully identify each studied modification. 
Characterization of major N-glycoforms. For most IgGs, glycosylation represents only 2 to 
3% of the total mass, but it can significantly influence the protein’s structure, immunogenicity 
and stability.33, 34 Glycosylation is also a class of mAb PTMs: here their study was described 
separately from amino acid PTMs because they are not considered degradation hot spots. To 
perform an advanced characterization of trastuzumab, an estimation of the ratio of the main 
glycoforms, as well as a structural determination is necessary. Trastuzumab is N-glycosylated on 
the Asn300 in the CH2 region.35-36 G0F and G1F, the major glycoforms found on human and 
recombinant IgG produced in CHO, NS0 and SP2/0 cells, represent more than 80% of the 
glycoforms.30, 37 Considering that Mascot search algorithm is only intended to identify the 
peptide sequences it was necessary to manually study the CESI-MS/MS data to identify the 
glycosylations and determine their structures. Interestingly, in this case as well, no extra 
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experiments needed to be performed to focus on glycopeptides. The same datasets used for 
peptide mapping and hot spots characterization were also used here. 
In conventional protocols, a mAb is commonly treated with PNGase F before analysis to 
release the glycans and allow study of them while not attached to the peptide backbone.37 In this 
work, the mAb was digested by trypsin only, and therefore we expected to detect glycans still 
linked to the corresponding peptide backbone of the HC. The extracted ion electropherograms 
(XIE) of the m/z ratio matching to the peptide TKPREEQYN300STYR bearing respectively the 
glycosylation G0F, G1F, G0F-GlcNac, G2F and G0 are shown in Figure 6 A-E, respectively. All 
the detected glycopeptides have a charge state of 3. 
The glycopeptides were detected between 26.3 and 28.5 min. The electrophoretic resolution 
calculated between the peaks corresponding to the glycopeptides bearing G0F and G1F gave a 
value of 0.88, while the resolution between the peaks of glycopeptides G1F and G2F gave a 
value of 1.08. These results demonstrate the separation of the glycopeptides G0F, G1F and G2F 
glycan having only one galactose difference in each case. The glycopeptide bearing G0 could 
also be observed on its corresponding XIE; however, this glycopeptide co-migrated with 
glycopeptides G0F. Moreover, the sensitivity provided by the CESI prototype allows detection of 
these glycopeptides with significant intensities and the signal was sufficient to generate good 
quality MS/MS spectra of each glycopeptides. More generally, these results allowed us to 
accurately locate the position of the glycosylation on Asn300 because it is the only potential 
glycosylation site on this peptide. The nature of the glycosylation, however, had to be confirmed 
using MS/MS data. 
MS/MS spectra (Figure 7) corresponding to the fragmentation of the different glycopeptides 
were subsequently extracted from the data. The precursor ion matches the mass of the 
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glycopeptide being glycosylated by G0F with a precision of 8.66 ppm. As expected with low 
energy collision induced dissociation (CID), product ions observed in MS/MS mainly 
correspond to the fragmentation of the glycan moiety and the peptide backbone is usually 
preserved. Study of the fragmentation spectra allowed us to deduce the structure of the glycan 
G0F. In the same manner, the MS/MS spectra of the glycopeptides bearing G1F, G2F and G0 
glycans were extracted from the data; in each case the mass measure precision on the precursor 
ion was inferior to 9.69 ppm. Similarly to the previous results, every ions corresponding to the 
different fragmentation of the glycan could be observed while the peptide backbone remained 
intact, allowing the structures of the studied glycans to be deduced. 
Results presented here demonstrate the possibility of using CE to separate and identify 
glycopeptides obtained from the trastuzumab enzymatic digestion mainly due to the baseline 
separation efficiency of the five major glycopeptides provided by the CE. As an additional 
benefit, the sensitivity provided by the CESI interface and the microTOFQ-II MS allowed us to 
obtain the complete fragmentation of the glycan and thereby deduce the structure of the five 
major glycans (G0F, G1F, G2F, G0F-GlcNac and G0). The same data was used for MS/MS 
peptide mapping and hot-spot characterization without requiring additional experiments. 
 
Discussion 
Peptide mapping is essential for the characterization of therapeutic mAbs, which are complex 
glycoproteins that contain a plethora of micro-heterogeneities due to the production process. In 
comparison to PMF, MS/MS peptide identification is not only based on digested peptide m/z 
ratio measure, but also on the fragmentation of those peptides, increasing the confidence of the 
identification. Capillary zone electrophoresis (CZE) separation is based on the migration of 
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species present in a background electrolyte (BGE) under an electrical field. Separation is 
obtained by differences in electrophoretic mobility among analytes depending on size and charge 
of the molecule at the BGE pH.  
Peptide mapping results showed the identification of wide variety of peptides regarding their 
chemical composition (Figure 2). This result indicates clearly that CE separation driven by 
peptide migration phenomena is able to separate and transfer successfully to the MS every 
digested peptide regardless of its nature. In RP-LC, small peptides (from one to two amino 
acids23) and more generally hydrophilic peptides, are often not detected because they are not 
retained on the column and elute in the void volume.19 The detection and identification of 
peptide such as LT09 or HT05 demonstrate the ability of CE to conserve and detect small 
peptides. The identification of the 63 amino acids peptide HT21 also demonstrates one of the 
advantages of using CE hyphenated to MS for peptide characterization. The presence of such 
large peptides is not surprising as trastuzumab HC does not have a tryptic cleavage site from 
amino acid 151 to 213. The elution and detection of such an imposing peptide may be difficult in 
RPLC-MS/MS because it can irreversibly interact with the stationary phase. Identification of 
very large peptides having no enzymatic digestion sites or corresponding to peptides or with 
several missed cleavages is also a very important asset of this method because 100% sequence 
coverage is obtainable in various cases. Indeed, some digestion sites in mAbs may not be 
accessible to trypsin due to the quaternary structure of the protein, which may cause missed 
cleavages during the digestion even when guanidine is present as a chaotropic reagent. In 
addition to the complete sequence coverage obtained of the HC and the LC, the sensitivity 
provided by the CESI prototype supported by the high resolution of the mass spectrometer 
allowed generation of high quality MS/MS spectra. This result is explained by a remarkable 
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ionization efficiency of the peptides. The low BGE flow rate during the separation indeed 
enhances the ionization process and reduces ion suppression.20,38 The spectral quality is reflected 
by the possibility of retracing the major part of the amino acid sequence in the variable domain. 
As the CESI-MS system is able to transfer efficiently an important number of ions, MS/MS 
spectra were of an excellent quality in terms of resolution and intensities (Figure 3). Therefore, a 
significant number of y/b fragments could be attributed, allowing retracing on the variable 
domain of the HC 109 of 120 amino acids and 98 of 107 on the LC. Understanding the variable 
domain of the mAb is crucial because it is directly involved in the antibody-antigen binding. It is 
noteworthy that such level of characterization could be attained with only one run of the CESI-
MS/MS system. 
Our results demonstrated the successful characterization of every single degradation hot spots 
on HC and LC and we observed in each case the partial modification of the protein because the 
modified and the intact form of the peptide could be identified (Figure 5). In the case of the 
glutamine cyclization of the N-terminal extremity on the HC, the CE separation mechanism 
allowed the separation of the modified and intact forms of the peptide based on conformational 
changes induced by glutamine cyclization. Such separation is explained by the fact that even if 
the mass difference between the parent and the modified peptide is only 17.02 Da, Glu 
cyclization involves the loss of the amine function on its lateral chain; therefore, there is a 
difference of one charge between glutamic acid and pyroglutamic acid because the amine is 
protonated in 10% acetic acid (pH 2.2). The possibility of separate the peptides prior to MS 
analysis, allows the identification of both forms. Indeed as the number of precursor ions selected 
for fragmentation per cycle is fairly limited on the microTOF-Q II, and taking into account the 
complexity of the sample, it would have been difficult for the MS to automatically select the m/z 
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ratio corresponding to both forms of this peptide during their detection window if they had co-
migrated. In the case of the deamidation hot spots present on Asn55 and Asn387 on the HC and 
Asn30 on the LC, the MS was able to fragment both the modified and the intact form for each 
peptide. Unlike in the glutamic acid cyclization, the XIE corresponding to those peptides (HT04, 
HT41 and LT03) showed in each case the complete co-migration between the intact peptide and 
its deamidated homologue. This is explained by the fact that the mass difference between 
asparagine and aspartic acid is only 0.98 Da. Regarding deamidation, the amide functional group 
located on asparagine lateral chain, is replaced by an alcohol function. Most importantly, there is 
thus no significant charge difference between the deamidated peptide and the intact peptide 
because those functions are protonated at BGE pH. In this case of oxidized Met255 (HT25) and 
Met431 (HT48), even if the detection times were not exactly the same for the intact peptide and its 
oxidized homologous, differences in electrophoretic mobilities could not lead to the baseline 
separation of those peptides. The sensitivity provided by the system allowed unambiguous 
characterization of each studied degradation hot spot, in addition to the low represented to PTMs 
and degradations present in small amounts. 
Using the CESI-MS/MS data, the complete structural characterization of the glycosylation 
G0F, G1F, G2F, G0F-GlcNac and G0 could be achieved (Figure 7). Because trypsin is not able 
to cleave glycosylation from the peptide, the glycan was observed on the corresponding digested 
peptide. The XIE corresponding to the glycopeptides bearing different glycans (Figure 6) 
demonstrated the separation of several glycopeptides in a reduced time. This result demonstrated 
the ability of the CE migration mechanism to completely separate glycopeptides having a 
difference of only one galactose ( e.g. between G0F and G1F). Such levels of separation could be 
explained by the fact that one more galactose leads to a difference between the two 
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glycopeptides in term of size (+ 162 Da). This difference affects their relative electrophoretic 
mobilities leading to their separation. The efficiency of CE in the glycopeptides separation has 
allowed the separation to be obtained in ~27 min. A difference of a fucose, however, did not lead 
to the separation of the glycopeptides G0F and G0, suggesting that the size of the glycopeptides 
is not significantly affected by the fucosylation at the BGE pH.  
To evaluate the robustness of this method, the analysis was consecutively repeated six times 
using the same mAb digest sample. Each analysis resulted in 100% sequence coverage in term of 
MS/MS peptide mapping. Similarly, the degradation hot spots identified were the same in each 
case and the five same major N-glycans could also be structurally characterized in the six 
analyses. Intensity ratios between the different glycopeptides were calculated for each analysis; 
the results exhibited a standard deviations ranging from 6 to 13%. Based on this results, 
glycopeptide intensities appear to be related to glycan distribution. It is therefore it is possible to 
consider profiling the mAb glycan using this very same CESI-MS/MS method, which would 
enriching the amount of information obtain from only one analysis.  
In conclusion, this work presents the development of a rapid and reliable method for 
performing a multi-level characterization of trastuzumab, which was used as reference 
therapeutic antibody in a single run. The mAb was digested using a conventional digestion 
protocol and the digest was analyzed by CESI hyphenated to a high resolution tandem MS. The 
CESI-MS/MS fragmentation obtained in only one acquisition allowed the complete amino acid 
sequence peptide map to be recorded. A Mascot search engine was used for peptide 
identification to provide a faster protocol. Also, the characterization of every PTM hot spot could 
be obtained within the same single run. Finally, separation of the major glycosylated peptides 
and their structural characterization could be obtained using the same CESI-MS/MS analysis 
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dataset. Such advanced characterization using only a single injection of 100 fmol of digested 
mAb peptide mixture in a 45 min analysis demonstrates the potential of CESI-MS as a fast and 
sensitive method in mAb characterization and more generally in bottom-up proteomic approach. 
 
Materials and methods 
Materials. All chemicals used were of analytical grade or high purity grade. Acetic acid was 
provided by VWR (Fontenay sous Bois, France). Bicarbonate ammonium, guanidine 
hydrochloride, iodoacetamide (IAM), dithiothreitol (DTT), trifluoroacetic acid, acetonitrile 
(ACN) and trypsin enzyme were purchased from Sigma-Aldrich (Saint Louis, MO, USA). Water 
used to prepare buffers and sample solutions was obtained using an ELGA purelab UHQ PS 
water purification system (Bucks, UK). Desalting steps were performed using C8 spin tips 
purchased from Protea Biosciences (Morgantown, WV, USA). 
Tryptic digestion procedure. Tryptic digests of antibodies were prepared using sequence-
grade trypsin (1:10 w/w) . Before digestion, sample was diluted to a concentration of 10 mg/mL. 
One mg of protein was mixed with 155 μL of denaturing reagent (guanidine HCl 6M in 50 mM 
ammonium bicarbonate) and 15 μL of DTT 100 mM were added. The mixture was incubated for 
5 minutes at 95°C, then cooled to ambient temperature. Then, 30 μL of IAM 100 mM was added 
and the mixture was placed in the dark for 20 minutes. Ten μL of trypsin was added and the 
mixture was incubated at room temperature for 3 hours; additional 10 μL of trypsin were added 
to the sample for overnight digestion at room temperature. Buffer exchange and concentration 
were performed using a C8 spin tips. Four hundred μL of mAb tryptic digest in BGE could be 
obtained. A volume of ten μL of the obtained digest was used to perform all CESI-MS/MS 
experiments. 
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Capillary Electrophoresis. The CE experiments were carried out with a PA 800 plus capillary 
electrophoresis (CE) system from Beckman Coulter (Brea, CA) equipped with a temperature 
controlled autosampler and a power supply able to deliver up to 30 kV. Hyphenation was 
realized using a CESI prototype made available by Beckman Coulter. Prototype of bare fused-
silica capillaries (total length 100 cm ; 30 μm i.d.) with characteristic porous tip on its final 3 cm 
supplied by Beckman Coulter (Brea, CA, USA), a second capillary (total length 80cm ; 50μm 
i.d.) filled during experiments with BGE allows electric contact. New capillaries were flushed for 
10 min at 75 psi (5.17 bar) with methanol, then 10 min with 0.1 M sodium hydroxide, followed 
10 min with 0.1 M hydrochloric acid and water for 20 min also at 75 psi. Finally, the capillary 
was flushed 10 min at 75 psi with BGEn which was acetic acid 10%. Hydrodynamic injection 
(69 mbar for 1 min) corresponding to a total volume of 11 nL of sample injected was used. 
Separations were performed using a voltage of +20 kV. 
Mass Spectrometry. For antibody characterization, the CESI system was coupled to a 
microTOF-Q II mass spectrometer (Bruker Daltonics, Bremen, Germany). The microTOF-Q II 
MS is equipped with a hybrid analyzer composed of a quadrupole followed by a time-of-flight 
(TOF) analyzer. Positive mode acquisition was used to detect precursor ions (MS) and 
fragmented product ions (MS/MS). Concerning the ESI source parameters, capillary voltage was 
set to -1.3 kV. Nebullizer gas was deactivated, the dry gas was set to 1.5 L/min and temperature 
of the source was set at 160 °C. Spectra were collected at a data acquisition frequency of 2 Hz; 
for fragmentation spectra, collision energy ranged from 0 to 45 V depending on the m/z ratio and 
charge state of the precursor ion. For each MS scan, 3 precursor ions were selected for 
fragmentation, and total duty cycle was therefore 2 sec. Mass range was 50 - 3000 for MS as 
well as MS/MS scans. 
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MS/MS data analysis. Data obtained from CESI-MS/MS experiments were processed using 
Mascot search algorithm developed by Matrix Science (Boston, MA, USA). Tryptic cleavage 
rules were applied for both HC and LC sequences of the mAb. Carbamidomethylation of 
cysteine (+57.02 Da) was selected as a fixed modification, N-deamidation of aspartic/isoaspartic 
acid (+0.985 Da) or succinimide intermediate (-17.03 Da) were selected as a variable 
modifications. Methionine oxidation (+15.99 Da) and N-terminal glutamic acid cyclization (-
17.02 Da) were also selected as variable modifications. The mass tolerance for precursor ions 
was set to ± 25 ppm and to ± 0.5 Da for fragments. A maximum of 3 missed cleavages was 
tolerated. MS/MS N-glycan identification and structural characterization were done manually. 
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 FIGURE LEGENDS 
Figure 1. Base Peak Electropherogram corresponding to the analysis by CESI-MS/MS of 
trastuzumab tryptic digest. Experimental conditions: bare fused silica capillary with porous tip, 
total length 95 cm (30 μm i.d., 150 μm o.d.); CE voltage +20 kV; BGE 10% acetic acid; sample 
trastuzumab tryptic digest 2.5 mg/mL in BGE (11nL injected).  MS capillary voltage: -1.3 kV, 
m/z range : 50 – 3000 
Figure 2. Sequence coverage obtained by CESI-MS/MS for trastuzumab HC (left-hand side) and 
LC (right-hand side) based on the identified peptides. Experimental conditions: see materials and 
methods 
Figure 3. List of trastuzumab digested peptides identified by the CESI-MS/MS analysis. 
Experimental conditions: see material and methods 
Figure 4. MS/MS spectra of peptide HT01 and HT02 illustrating the amino acid sequence 
retracing in the variable domain. Experimental conditions: see material and methods. 
Figure 5. MS/MS spectra of peptide HT04 (LLIYSASFLYSGVPSR) A) without modification 
and B) with a deamidation on Asn55 illustrating the partial modification of the mAb and the 
characterization of both forms by CESI-MS/MS. Experimental conditions: see material and 
methods. 
Figure 6. Extracted Ion Electropherogram of m/z ratios A) 1039.80 (HT29 + G0F), B) 1093.78 
(HT29 + G1F), C) 972.09 (HT29 + G0), D) 1147.82 (HT29 + G2F), E) 991.10 (HT29 + G0). 
Experimental conditions: see material and methods. 
Figure 7. MS/MS fragmentation spectra of A) HT29 - G0F (precursor m/z 1039.78; charge state 
3+),  B) HT29 - G1F (precursor ion 1093.80; charge state 3+), C) HT29 - G2F (precursor ion 
1147.82; charge state 3+), D) HT29 - G0F-GlcNac (precursor ion 972.10; 3+), D) HT29 - G0 
(precursor ion 991.09; charge state 3+). Experimental conditions described in material and 
methods section. 
 







